search
Back to results

Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer. (e-ONCOGITE)

Primary Purpose

Breast Cancer

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Cognitive remediation
Sponsored by
Institut Bergonié
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Breast Cancer focused on measuring Cognition

Eligibility Criteria

20 Years - 60 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Women aged 20 to 60 years inclusive. Localised breast cancer having required neoadjuvant or adjuvant chemotherapy, the last cycle of which took place between 2 and 24 months prior to inclusion. Informed consent dated and signed. Patient with French social security cover in accordance with French law on biomedical research (Article 1121-11 of the French code of public health). Exclusion Criteria: Metastatic breast cancer. Presence of unstable psychiatric or neurological disorders likely to affect cognition (information requested directly from the participant) History of drug abuse. Patient who cannot read or understand French. Patient already included in this study. Patient having participated in onCOGITE workshops. Patient participating in another clinical trial evaluating cognitive remediation. Patient deprived of freedom or subject to legal protection measures (under guardianship, in custody of the court, or family-member guardianship order).

Sites / Locations

  • Institut Bergonié, Comprehensive Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Group 1 (Cognitive remediation)

Group 2 (No cognitive remediation)

Arm Description

Outcomes

Primary Outcome Measures

Number of participants with improved quality of life (Emotional and functional QoL)
Improved QoL is defined as a significant improvement (i.e. at least a 3-point increase of the total score) in both the Emotional Well-Being (EWB) and Functional Well-Being (FWB) subscales of the FACT-B self-questionnaire (Functional Assessment of Cancer Therapy -Breast - Brady et al. J Clin Oncol 1997).

Secondary Outcome Measures

Number of participants with improved quality of life (physical QoL)
Improved QoL is defined as a significant improvement (i.e. at least a 3-point increase of the total score) in the physical Well-Being subscale of the FACT-B self-questionnaire (Functional Assessment of Cancer Therapy -Breast - Brady et al. J Clin Oncol 1997).
Number of participants with improved quality of life (Social/family QoL)
Improved QoL is defined as a significant improvement (i.e. at least a 3-point increase of the total score) in the Social/family subscale of the FACT-B self-questionnaire (Functional Assessment of Cancer Therapy -Breast - Brady et al. J Clin Oncol 1997).

Full Information

First Posted
January 10, 2023
Last Updated
February 20, 2023
Sponsor
Institut Bergonié
Collaborators
University of Bordeaux, Association Oncogite
search

1. Study Identification

Unique Protocol Identification Number
NCT05690828
Brief Title
Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer.
Acronym
e-ONCOGITE
Official Title
Etude e-ONCOGITE : Évaluation d'Une Prise en Charge Cognitive adaptée au " Chemobrain" Chez Des Patientes traitées Pour un Cancer de Sein.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2023 (Actual)
Primary Completion Date
June 1, 2024 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut Bergonié
Collaborators
University of Bordeaux, Association Oncogite

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This project will investigate the efficacy of a cognitive remediation programme in patients treated for breast cancer. patients will be randomized between "no intervention" and "intervention programme". Efficay will be assessed in term of improved quality of life.
Detailed Description
Medical progress in the treatment of cancer has prolonged patients' life expectancy. This improvement has led researchers to become concerned about the long-term negative effects of cancer treatments on quality-of-life. In particular, previous studies have identified complaints that have been submitted concerning the cognitive status of patients treated with chemotherapy (Berglund et coll., 1991). All of these cognitive changes are collectively grouped under the term chemobrain. The consequences of treatments remain however underestimated, as the priority when diagnosing cancer remains the patient's short- to medium-term survival; yet, quality-of-life contributes to the long-term survival of patients (Kramer, 2000). In addition to medical treatments, psychosocial care adapted to the specific needs of subjects is thus important for improving their quality-of-life and helping them return to work. Even if initiatives have multiplied over the past few decades in the psychosocial management of these subjects (e.g., supportive care), that related to cognitive disorders in subjects having survived cancer remains a little documented field. Cognitive deficiency in cancer survivors is said to be moderate (Razaq et coll., 2017), which makes survivors ideal candidates for cognitive rehabilitation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
Cognition

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
164 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group 1 (Cognitive remediation)
Arm Type
Experimental
Arm Title
Group 2 (No cognitive remediation)
Arm Type
No Intervention
Intervention Type
Behavioral
Intervention Name(s)
Cognitive remediation
Intervention Description
The cognitive remediation programme shall be run either in video workshops or face to face workshops and in home sessions via a web app. The programme will run for 4 months during which there will be 3 different evaluations. A first evaluation after randomisation, a second evaluation 4 months after inclusion (corresponding to the end of the programme), and a third evaluation 8 months after inclusion for the experimental group (4 months after the end of the programme). The face to face workshops will take 8 to 10 participants and will be led by a neuropsychologist.
Primary Outcome Measure Information:
Title
Number of participants with improved quality of life (Emotional and functional QoL)
Description
Improved QoL is defined as a significant improvement (i.e. at least a 3-point increase of the total score) in both the Emotional Well-Being (EWB) and Functional Well-Being (FWB) subscales of the FACT-B self-questionnaire (Functional Assessment of Cancer Therapy -Breast - Brady et al. J Clin Oncol 1997).
Time Frame
4 months after initiation of the cognitive stimulation protocol using the "onCOGITE" method
Secondary Outcome Measure Information:
Title
Number of participants with improved quality of life (physical QoL)
Description
Improved QoL is defined as a significant improvement (i.e. at least a 3-point increase of the total score) in the physical Well-Being subscale of the FACT-B self-questionnaire (Functional Assessment of Cancer Therapy -Breast - Brady et al. J Clin Oncol 1997).
Time Frame
4 months after initiation of the cognitive stimulation protocol using the "onCOGITE" method
Title
Number of participants with improved quality of life (Social/family QoL)
Description
Improved QoL is defined as a significant improvement (i.e. at least a 3-point increase of the total score) in the Social/family subscale of the FACT-B self-questionnaire (Functional Assessment of Cancer Therapy -Breast - Brady et al. J Clin Oncol 1997).
Time Frame
4 months after initiation of the cognitive stimulation protocol using the "onCOGITE" method

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women aged 20 to 60 years inclusive. Localised breast cancer having required neoadjuvant or adjuvant chemotherapy, the last cycle of which took place between 2 and 24 months prior to inclusion. Informed consent dated and signed. Patient with French social security cover in accordance with French law on biomedical research (Article 1121-11 of the French code of public health). Exclusion Criteria: Metastatic breast cancer. Presence of unstable psychiatric or neurological disorders likely to affect cognition (information requested directly from the participant) History of drug abuse. Patient who cannot read or understand French. Patient already included in this study. Patient having participated in onCOGITE workshops. Patient participating in another clinical trial evaluating cognitive remediation. Patient deprived of freedom or subject to legal protection measures (under guardianship, in custody of the court, or family-member guardianship order).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Véronique GERAT-MULLER, PhD
Phone
0556337804
Email
v.gerat-muller@bordeaux.unicancer.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Simone MATHOULIN-PELISSIER, MD/PhD
Email
s.mathoulin@bordeaux.unicancer.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Véronique GERAT-MULLER, PhD
Organizational Affiliation
v.gerat-muller@bordeaux.unicancer.fr
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institut Bergonié, Comprehensive Cancer Center
City
Bordeaux
Country
France
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer.

We'll reach out to this number within 24 hrs